Axes 1–2 · Brand Index
Conditional score and coverage
Opacity share 0.0%. Brand results are not ordered when coverage bounds overlap. A brand-level sensitivity interval is undefined because the release preserves formulation-level intervals.
brand · release 2026-09-20
Marco Pharma Int'l
Structured fields rendered from the release dataset. Unknown values retain a reason; price is outside GIS.
Formulations4
Conditional mean GIS67.38
Coverage75.0%
Axes 3–4
Measurement status and document panel
Not a measurement product, so this axis does not apply.
No brand review panel is published in this release.
Price column
Brand price aggregation
undefined: prices are retained at label-version level and are not averaged across formulations.
Brand profile
What this brand's labels look like as a set
- Potency basis
- The potency basis is not stated. 5 · counted across 5 organism rows on its labels, not across products
- Printed CFU across its labels
- 300,000,000 – 750,000,000; median 525,000,000. Measured on the 2 of 5 organism rows that print a per-organism figure; labels stating only a blend total are not in this range.
- Forms
- Capsule: 2 · Tablet or Pill: 1 · counted across the 3 of 3 products whose label states a form
- Observed prices
- 0 of 3 published products
- Printed claims per label
- 1.3 on average across the 3 of 3 products whose label carries a parsed claim block. A printed claim is not evidence and enters no axis.
Products
Published product pages of this brand
| Product | Gut Index Score |
|---|---|
| Marco Pharma Int'l Ba-Co-Flor | 67.38 |
| Marco Pharma Int'l Intesta Cleanse | 73.00 |
| Marco Pharma Int'l Kiddi-Flora | 61.75 |
Organisms
What this brand actually puts on its labels
Across its published products, 3 distinct organisms or ingredients are printed. The most frequent, with the number of published products carrying each:
| Organism or ingredient | Published products of this brand |
|---|---|
| Bacillus coagulans | 3 |
| inulin | 1 |
| Lactobacillus sporogenes | 1 |
Elsewhere in this release
Related pages
Findings computed over the whole corpus: Potency basis census · Supplier code network · Label designation changes
Tools: DSLD product check
Citation
Cite this page
Ivitskiy, I. (2026). Marco Pharma Int'l. Gut Registry, release 2026-09-20. Elanvale Ltd. https://gutregistry.com/b/marco-pharma-int-l/
The underlying tables are published under CC BY 4.0: this page as CSV · as JSON · full release and data dictionary. Cell-level provenance names the source record and its observation date.
Citable atoms
Release claims
Marco Pharma Int'l has 4 eligible SKUs and 4 formulation groups among labels in the NIH DSLD snapshot (Sep 2026).
4 / 4 formulation groups · NIH DSLD snapshot Sep 2026 · brand.skus · checked 2026-09-20T00:00:00Z · snapshot b7633f7324370 of 4 Marco Pharma Int'l formulation groups have at least one printed strain designation (0.0%) in the NIH DSLD snapshot Sep 2026.
0 / 4 formulation groups · NIH DSLD snapshot Sep 2026 · brand.naming · checked 2026-09-20T00:00:00Z · snapshot b7633f7324370 of 4 Marco Pharma Int'l formulation groups were scored using the available matching evidence (0.0%) in the NIH DSLD snapshot Sep 2026.
0 / 4 formulation groups · NIH DSLD snapshot Sep 2026 · brand.opacity · checked 2026-09-20T00:00:00Z · snapshot b7633f732437Marco Pharma Int'l: conditional Brand Index 67.38 from 3 of 4 formulation groups with numeric Gut Index Scores (75.0%); unscored groups remain outside the mean. Window: NIH DSLD snapshot Sep 2026.
3 / 4 formulation groups · NIH DSLD snapshot Sep 2026 · brand.index · checked 2026-09-20T00:00:00Z · snapshot b7633f732437